INTRODUCTION
Cancer and its treatment may induce psychological distress often associated with adjustment disorders, anxiety, or depression disorders. Although antidepressants may be effective in the treatment of major depressive disorders, little is known about the respective efficacy and safety of antidepressants and benzodiazepines in the treatment of adjustment disorders in cancer patients. Antidepressants may be appropriate psychotropic medication due to the multiplicity of their actions, e.g. antidepressant, anxiolytic and sedative. Trazodone, a selective serotonin reuptake inhibitor with specific antagonism against 5-HT 2(a _ c) postsynaptic receptors, combines antidepressant activity with significant anxiolytic and sedative effects, and its use seems to be efficacious in the treatment of psychological distress. ' The efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients were compared in a pilot, double-blind study and are reported in this study.
PATIENTS AND METHODS

PATIENTS
The study population comprised female patients diagnosed with breast cancer and who were receiving treatment for this condition. To be included, patients had to meet the Diagnostic and Statistical Manual of Mental Disorders (3rd edn., revised; DSM-III-R) criteria for adjustment disorders with anxious or depressed mood and/or mixed disturbance of emotion and conduct. Patients also had to have a score of~14 on the French version of the Hospital Anxiety and Depression Rating Scale (HADS).2.3 Patients were not eligible if they had a 265 clinically significant history of serious psychiatric disorders, or if they were receiving psychiatric or psychoactive medication; zolpidem use was permitted if the dose was constant 7 days prior to study entry.
STUDY DESIGN AND DRUG ADMINISTRATION
The protocol was approved by the Ethics Committee of the Jules Bordet Institute and the study was conducted in accordance with the European Good Clinical Practice guidelines and the current version of the Declaration of Helsinki.
At visit 1, patients gave informed consent and, after review of inclusion and exclusion criteria, were assigned to receive either trazodone or clorazepate according to a computer-generated randomization list prepared prior to the start of the study. The dosing schedule was one capsule (containing trazodone 50 mg or clorazepate 10 mg, according to treatment group) on day 1 and day 2, two capsules on day 3 and day 4, and three capsules per day from day 5 to day 28. Study medication was taken once daily with an evening meal or at bedtime with a snack.
PATIENT ASSESSMENT
Treatment effects were evaluated after 14 days (visit 2) and 28 days (visit 3, end-point) and were compared with baseline values (visit 1). Four clinical scales were used to assess patients: the French version of HADS;2,4 the Revised Symptom Checklist (SCL-90-R);5 the EORTC Quality of Life Questionnaire (QLQ-C30);6 and Clinical Global Impression (CG!).
The primary objective of the study was to determine whether there was a higher incidence of successful responses with 
SAFETY
The tolerance of each treatment was assessed by recording weight, blood pressure, pulse rate and spontaneously reported adverse events.
STATISTICAL ANALYSIS
Patients were evaluated on an intent-to-treat basis. Fisher's exact test was used to compare the incidence of successful responses between treatment groups, and point and confidence intervals (CI) were calculated for the corresponding odds ratio. Changes in clinical scale scores and subscores were assessed using multivariate analysis of variance (MANOVA) and the Wilcoxon test. Bayesian analysis supplemented classic statistical methods; the parameters of interest were the success probabilities in each treatment group. Before the start of the trial, the investigator recorded the plausibility of every possible value for each treatment success probability. These prior beliefs were then translated into a mathematical form, which resulted in the prior distribution. After completion of the study, the results and the prior distribution were combined to produce the posterior distribution, whereby the plausibility of the parameters was updated. In this paper, the ratio of the trazodone success probability to the clorazepate success probability, which determines 266 the relative risk (RR), was used to express the posterior distribution.
RESULTS
In this study, 27 patients were enrolled; however, nine were not included in the efficacy analysis. Major protocol violations resulted in the withdrawal of six patients (three patients took unauthorized drugs, two of whom were men and should not have been included, and one patient had alkaline phosphatase levels of 469 DIll [hepatic metastases]), two patients refused to take the study medication and one patient was lost to follow-up almost immediately after inclusion. Henceforth, all results of efficacy analysis are based on 18 patients; 11 were randomized to receive trazodone and seven were administered clorazepate.
All female patients who received study medication were included in the safety analysis, except the one who was lost to follow-up almost immediately after inclusion. As two patients did not take study medication, safety results are based on 23 patients (13 in the trazodone group, 10 in the clorazepate group).
Among the 18 patients included in the efficacy analysis, only one patient in the trazodone group did not attend the three scheduled visits and stopped treatment after 5 days due to adverse events. For all other patients, visit 2 took place within 1 day of the scheduled time and visit 3 was either on day 28 or day 29. The mean once-daily dose of trazodone was 111.5 ± 36.3 mg and clorazepate 17.5 ± 7.5 mg.
BASELINE ASSESSMENT
All patients were female and Caucasian. The median age was 56.5 years (range 33 -71 years); there was no significant difference between treatment groups. Median weight and height of patients in the trazodone group D Razavi, N Kormoss, A Collard et al.
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was 57 kg and 163 cm, respectively, and in the clorazepate group 65 kg and 164 cm, respectively; no significant differences in height or weight were detected between treatment groups. Life expectancy was > 6 months for six (54.5%) patients in the trazodone group and for two (28.6%) in the clorazepate group. Eight (72.7%) patients in the trazodone group and five (71.4%) patients receiving clorazepate were ambulatory. Medical history of neoplastic disease was similar in both treatment groups. Five patients (four receiving trazodone and one treated with clorazepate) took zolpidem for sleep disorders at least 1 week before visit 1. All patients suffered from an adjustment disorder according to the DSM-III-R criteria and had a score of~14 on the HADS; baseline values for HADS scores were compared using the Wilcoxon test but no significant difference was detected. The predominant symptoms in 16 (88.8%) patients in the intent-to-treat population of 18 were various combinations of anxiety, depression and other emotions, with 10 (91 %) patients in the trazodone group and six (85.7%) in the clorazepate group classified under the category of 'mixed emotional features'. The remaining patient in the trazodone group had an adjustment disorder with depressed mood, whereas the last patient in the clorazepate group presented an adjustment disorder with anxious mood. There was no significant difference between either group regarding the adjustment disorder.
PRIMARY END-POINT
Using the definition of a successful response, as given in Patients and Methods, the observed success rate for trazodone was 90.9% (10/11) and for clorazepate 57.1 % (four of seven). The response rates were not significantly different, probably because of the 267 small number of patients included (Fisher's exact test, P = 0.14). The estimated odds ratio was 7.5 with associated 95% CI (0.59, 95.43).
The investigator's prior opinion about treatment success probabilities was that any values within a particular CI range were equally likely. For trazodone, the CIs were (0.6, 0.9) and for clorazepate (0.45, 0.85). The prior density for the relative risk showed a mode located at 1.05, which is barely above the equivalence point RR = 1. From the constraints imposed on the range of each individual success probability, the corresponding range for RR was derived to be (0.7, 2). The prior probability that trazodone was less successful than clorazepate (i.e. RR < 1) was 0.26. The posterior density is coherent with the prior density and hence values of RR outside (0.7, 2) have zero plausibility. The posterior mode was updated to 1.22, and the posterior probability that trazodone was less successful than clorazepate was updated to 0.08. When the constraints on the range imposed by the prior choice of the investigator were relaxed, the conclusions obtained were not changed, thus small quantitative changes in the prior distribution did not alter the conclusions.
SECONDARY END-POINTS
During the first 2 weeks, the decrease of total HADS scores was lower with trazodone compared with clorazepate (P < 0.001, MANOVA), but after this time-point the total score remained stable in the trazodone group and moderately increased with clorazepate treatment. This trend was not significant because of the small number of patients ( Table 1) .
At inclusion, the Global Severity index (GSI) was similar in both treatment groups and at end-point the decrease was more pronounced in the trazodone group ( (-0.34, Table 2 ); however, this was not significant (Wilcoxon test, P = 0.25). There was a similar pattern for the Positive Symptom total and the Positive Symptom Distress index. Baseline and end-point values for nine primary symptom dimensions are also shown in Table 2 . The antidepressive effect of trazodone appeared more marked in the analysis of three primary symptom dimensions: depression; anxiety; and interpersonal sensitivity. The decrease in phobic anxiety and anxiety was also greater in the trazodone group in comparison with the clorazepate group. The interpersonal sensitivity scores were approximately equivalent at baseline; however, at end-point more subscores in the trazodone group showed a decrease (not significant).
Quality of life assessed using the QLQ-C30 scale is shown in Table 2 . The improvement in patient health status and quality-of-life global score was more marked in the trazodone group, whereas the functional and symptom mean scores were very similar in both treatment groups. Global quality of life and health status was compared between treatment groups using MANOVA, but no significant treatment effect was detected.
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SAFETY
At least one adverse event whose relation to study medications was rated as 'probable' or 'uncertain' was recorded in nine patients (five in the trazodone group and four in the clorazepate group). One patient who received trazodone withdrew from the study after 5 days due to adverse events (severe vertigo and pulsation in the head) that were probably related to the study medication. A dose adjustment due to adverse events (sleepiness, aggressiveness and disinhibition) was required in one of 13 (7.6%) patients in the trazodone group and three of 10 (30.0%) patients receiving clorazepate. No significant difference was observed between treatment groups concerning safety and frequency of adverse events (Table 3 ). There were no clinically relevant differences in blood pressure, pulse rate, or weight between either group.
DISCUSSION
This study showed that the number of successful responses was higher with trazodone compared with clorazepate. The difference was not significant, and this may be due to the small sample size and the heterogeneity of the studied in-and outpatient population. Classic statistical analysis did not confirm the hypothesis that trazodone is more efficacious than clorazepate; either because there was no difference in efficacy between the two treatments or because any change was not sufficient to result in statistical significance. This conclusion was nuanced with Bayesian analysis, which enabled assessment of a treatment differential from a small sample and encompassed the investigator's expectation of a low improvement with trazodone compared with the standard therapy of clorazepate. Sparse data permit only an inference and, although Bayesian analysis does not compensate for a lack of observations," some conclusions can 270 be made: results from the trial confirmed the prior beliefs and strengthened the presumed advantage of trazodone over clorazepate.
The prior probability of making a wrong decision in prescribing trazodone rather than clorazepate was updated from 26% to 8%. Whether this decrease is sufficient for trazodone to replace the standard treatment of clorazepate is still a matter of judgement and, in this respect, changes in the clinical scales (HADS, SCL-90-R and QLQ-C30) are important to consider.
The SCL-90-R is scored and interpreted in terms of nine primary dimensions and three global indices of distress. The nine primary symptom dimensions (somatization, obsessivecompulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoia and psychoticism) essentially D Bazavi, N Kormoss, A Collard et al.
Trazodone versus clorazepate for adjustment disorders in cancer patients provide a broad profile of the patient's status in psychopathological terms. The global indices are: the Global Severity index, which combines information on numbers of symptoms and intensity of perceived distress; the Positive Symptom total, which is simply a count of the number of symptoms the patient reports as positive, i.e, that the patient experiences as having to any degree; and the Positive Symptom Distress index, which is a pure intensity measure corrected for the number of symptoms.
Quality of life measured using the QLQ-C30 scale incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social); three symptom scales (fatigue, pain and nausea/ vomiting); and a global health status and quality of life score, which ranges from 0 to 100 with a higher score indicating a higher level of functioning.
Although comparison of clinical scale scores at baseline and end-point did not indicate significance, trazodone was found to be the more favourable treatment. Qualityof-life assessment, for example, which is becoming increasingly important for cancer patients due to the efficacy of treatments prolonging survival, revealed a positive trend with trazodone treatment in this shortterm 28-day study; however, longer-term studies are required to identify any benefits. Analysis of the SCL-90-R scores revealed that depression and anxiety were better controlled by trazodone than by clorazepate. Regarding safety and tolerability, few adverse events were reported and were generally not severe; only one patient withdrew from the study due to adverse events. In conclusion, trazodone may be an alternative to clorazepate for treating adjustment disorders in cancer patients.
